Lemborexant: First Approval

被引：0
作者：
Lesley J. Scott
机构：
[1] Springer Nature,
来源：
Drugs | 2020年 / 80卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its first approval (with final interim scheduling) in the USA for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. In January 2020, lemborexant also received approval in Japan for the treatment of insomnia. It is also being investigated for the treatment of irregular sleep-wake rhythm disorder (ISWRD) associated with mild to moderate Alzheimer’s disease. This article summarizes the milestones in the development of lemborexant leading to its first global approval.
引用
收藏
页码：425 / 432
页数：7
相关论文
共 66 条
[1]  
Morin CM(2015)Insomnia disorder Nat Rev. 1 1-18
[2]  
Drake CL(2018)Insomnia in elderly patients: recommendations for pharmacological management Drugs Aging. 35 791-817
[3]  
Harvey AG(2019)Pharmacotherapy for insomnia disorder in older adults JAMA Netw Open. 2 e1918214-266
[4]  
Abad VC(2011)Orexin receptors: pharmacology and therapeutic opportunities Annu Rev Pharmacol Toxicol. 10 243-4664
[5]  
Guilleminault C(2018)The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases Front Mol Neurosci. 11 220-295
[6]  
Grandner MA(2015)Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)- J Med Chem. 58 4648-104
[7]  
Perlis ML(2017)-(5-fluor opyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist J Pharmacol Exp Ther. 362 287-S264
[8]  
Scammell TE(2019)In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist Sleep. 42 zsz076-S97
[9]  
Winrow CJ(2017)Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation J Clin Pharmacol. 57 96-A150
[10]  
Wang C(2019)Concentration-response modeling of ECG data from early-phase clinical studies as an alternative clinical and regulatory approach to assessing QT risk: experience from the development program of lemborexant Clin Pharmacol Ther. 105 S54-A151
1234567